Pharmaceutical News

RSS

Qatari study finds BNT162b2 vaccine effectiveness waning 6 months after second dose

The researchers assessed the effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection and COVID-19-related hospitalization and deaths.

10 Oct 2021

Low risk of severe COVID-19 after first dose of Pfizer and AstraZeneca vaccines in Scotland

Hospital admissions and deaths due to COVID-19 were drastically reduced at two weeks or more from the first dose of either the Pfizer or AstraZeneca vaccine.

10 Oct 2021

Quantifying the Impact of Powder Properties on Pharmaceutical Powders

Powder processing lies at the heart of pharmaceutical manufacture. It is therefore necessary that efforts to improve efficiency and preserve quality must focus on understanding and controlling powder behaviour.

From Freeman Technology 7 Oct 2021

Moderna COVID vaccine booster dose results in immune memory

A recent study presents evidence that a booster dose of the Moderna vaccine can induce a robust memory immune response against COVID-19.

6 Oct 2021

Thrombolytic therapy may be safe for people with ischemic stroke and unruptured aneurysms

Clot-busting drugs are the main treatment for stroke, but they have often not been recommended for people who have an aneurysm in their brains that has not ruptured. An aneurysm is a bulge in the wall of a blood vessel in the brain.

6 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.

5 Oct 2021

New study underscores the importance of improving COVID-19 vaccination rates worldwide

Two doses of Pfizer-BioNTech (BNT162b2) are 90% effective against COVID-19 hospitalizations for all variants, including delta, for at least six months, confirms a new study from Kaiser Permanente and Pfizer published in The Lancet.

5 Oct 2021

Moderna's COVID-19 vaccine proves effective against multiple SARS-CoV-2 variants, including delta

Researchers in the United States have demonstrated the real-world effectiveness of Moderna’s mRNA-1273 vaccine at protecting against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and preventing hospitalization due to coronavirus disease 2019 (COVID-19).

4 Oct 2021

J&J vaccine prevents SARS-CoV-2-induced thrombosis and inflammation in hamsters

In a recent study, researchers performed bulk RNA-Seq transcriptomic profiling of lungs from vaccinated and unvaccinated hamsters with the Janssen vaccine.

4 Oct 2021

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

A recent study assesses the serological and cellular responses to Pfizer’s BNT162b2 mRNA vaccine in people aged 80-96 years.

4 Oct 2021

Psychedelic drug changes the emotional state of people listening to music

Scientists have found that the psychedelic drug psilocybin, in development as an anti-depressive treatment, changes the emotional state of people listening to music.

4 Oct 2021

Existing drug used to treat constipation may boost people's ability to think more clearly

The development of drugs to treat cognitive problems in patients with mental illness may be a step closer after a team of researchers discovered that an existing drug - used to treat constipation - may be able to boost our ability to think more clearly.

4 Oct 2021

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

The phase 1-2 clinical trials conducted using REGEN-COV had shown promising therapeutic benefits in COVID-19 outpatients. Its effect was further investigated in the present phase 3 clinical trial, the findings of which have been published in the "The New England Journal of Medicine".

3 Oct 2021

Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).

2 Oct 2021

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.

1 Oct 2021

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

A promising study shows that a combination of two monoclonal antibodies effectively neutralized SARS-CoV-2 in monkeys and proved efficacious against newer variants of concern in vitro.

1 Oct 2021

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

Coronavirus research has shown that higher viral loads are associated with severe COVID-19 infection. But new results from the phase III Coronavirus Efficacy (COVE) clinical trial find the Moderna vaccine reduces severe acute respiratory coronavirus 2 (SARS-CoV-2) viral load and viral shedding.

30 Sep 2021

50-year-old UK Misuse of Drugs Act failed to reduce illicit drug supply, expert says

The 50-year-old UK Misuse of Drugs Act, which provides the primary legislation for our drug laws, has failed to reduce illicit drug supply, use, and harms and was designed, and continues to be used, as a tool of systemic racism, argues Lord Simon Woolley in The BMJ today.

30 Sep 2021

Pharmaceutical News

Qatari study finds BNT162b2 vaccine effectiveness waning 6 months after second dose

Low risk of severe COVID-19 after first dose of Pfizer and AstraZeneca vaccines in Scotland

Quantifying the Impact of Powder Properties on Pharmaceutical Powders

Moderna COVID vaccine booster dose results in immune memory

Thrombolytic therapy may be safe for people with ischemic stroke and unruptured aneurysms

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

New study underscores the importance of improving COVID-19 vaccination rates worldwide

Moderna's COVID-19 vaccine proves effective against multiple SARS-CoV-2 variants, including delta

J&J vaccine prevents SARS-CoV-2-induced thrombosis and inflammation in hamsters

How durable is the immune response generated from the BNT162b2 vaccine?

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

Psychedelic drug changes the emotional state of people listening to music

Existing drug used to treat constipation may boost people's ability to think more clearly

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

50-year-old UK Misuse of Drugs Act failed to reduce illicit drug supply, expert says

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News